Hereditary Angioedema Therapeutics Current And Future Research In The World

The global hereditary angioedema therapeutic market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Access Full Info @ https://www.grandviewresearch.com/industry-analysis/hereditary-angioedema-hae-therapeutics-market/request/rs1

 

Further key findings from the report suggest:

• The C1-esterase inhibitor segment held the largest share in 2018 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
• On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
• Based on route of administration, intravenous drug therapies was one of the largest segments. Subcutaneously-administered therapies, on the other hand, are estimated to exhibit a lucrative CAGR of over 9.0% during the forecast period owing to benefits such as convenient dosing and improved drug effectiveness
• North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2018. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
• Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
• Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Grand View Research has segmented the global hereditary angioedema therapeutics market on the basis of drug class, treatment type, route of administration, and region:

Hereditary Angioedema Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2026)

• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor